{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:38:17Z","timestamp":1769013497646,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015283","name":"Bloomberg Philanthropies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s11606-025-09356-2","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:04:30Z","timestamp":1737475470000},"page":"3111-3117","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5682-9625","authenticated-orcid":false,"given":"Olivia K.","family":"Sugarman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risha","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachini","family":"Bandara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"2","key":"9356_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1377\/hlthaff.2018.05232","volume":"38","author":"D Powell","year":"2019","unstructured":"Powell D, Alpert A, Pacula RL. A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C. Health Affairs. 2019;38(2):287-294. https:\/\/doi.org\/10.1377\/hlthaff.2018.05232","journal-title":"Health Affairs."},{"key":"9356_CR2","unstructured":"Centers for Disease Control and Prevention. Figure 3.1. Number of reported cases of acute Hepatitis C virus infection and estimated infections - United States, 2014\u20132021. July 27, 2023. Accessed February 15, 2024. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c\/figure-3.1.htm"},{"key":"9356_CR3","unstructured":"Centers for Disease Control and Prevention. Table 3.3. Reported risk behaviors or exposures among reported cases of acute Hepatitis C virus infection - United States, 2021. July 27, 2023. Accessed February 15, 2024. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2021surveillance\/hepatitis-c\/table-3.3.htm"},{"issue":"2","key":"9356_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11904-018-0390-3","volume":"15","author":"DC Perlman","year":"2018","unstructured":"Perlman DC, Jordan AE. The syndemic of opioid misuse, overdose, HCV and HIV: Structural-level causes and interventions. Curr HIV\/AIDS Rep. 2018;15(2):96-112. https:\/\/doi.org\/10.1007\/s11904-018-0390-3","journal-title":"Curr HIV\/AIDS Rep."},{"issue":"2","key":"9356_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","volume":"108","author":"JE Zibbell","year":"2018","unstructured":"Zibbell JE, Asher AK, Patel RC, et al. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-181. https:\/\/doi.org\/10.2105\/AJPH.2017.304132","journal-title":"Am J Public Health."},{"issue":"4","key":"9356_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, et al. Glecaprevir\u2013Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine. 2018;378(4):354-369. https:\/\/doi.org\/10.1056\/NEJMoa1702417","journal-title":"New England Journal of Medicine."},{"issue":"27","key":"9356_CR7","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New England Journal of Medicine. 2015;373(27):2599-2607. https:\/\/doi.org\/10.1056\/NEJMoa1512610","journal-title":"New England Journal of Medicine."},{"key":"9356_CR8","doi-asserted-by":"publisher","unstructured":"National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. (Michelle Mancher, ed.). National Academies Press; 2019. https:\/\/doi.org\/10.17226\/25310","DOI":"10.17226\/25310"},{"key":"9356_CR9","doi-asserted-by":"publisher","first-page":"932306","DOI":"10.3389\/fpsyt.2022.932306","volume":"13","author":"P Losikoff","year":"2022","unstructured":"Losikoff P, Bosse JD, Martin SA, Wilson A, Chiodo LM. Integrated hepatitis C treatment is associated with improved retention and success in outpatient treatment for opioid use disorder at a private clinic. Front Psychiatry. 2022;13:932306. https:\/\/doi.org\/10.3389\/fpsyt.2022.932306","journal-title":"Front Psychiatry."},{"key":"9356_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jsat.2017.01.015","volume":"75","author":"B Norton","year":"2017","unstructured":"Norton B, Beitin A, Glenn M, DeLuca J, Litwin A, Cunningham C. Retention in Buprenorphine Treatment is Associated with Improved HCV Care Outcomes. J Subst Abuse Treat. 2017;75:38-42. https:\/\/doi.org\/10.1016\/j.jsat.2017.01.015","journal-title":"J Subst Abuse Treat."},{"issue":"7","key":"9356_CR11","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/cid\/ciaa105","volume":"71","author":"ES Rosenthal","year":"2020","unstructured":"Rosenthal ES, Silk R, Mathur P, et al. Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs. Clin Infect Dis. 2020;71(7):1715-1722. https:\/\/doi.org\/10.1093\/cid\/ciaa105","journal-title":"Clin Infect Dis."},{"issue":"12","key":"9356_CR12","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1001\/jamainternmed.2014.5416","volume":"174","author":"JI Tsui","year":"2014","unstructured":"Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users. JAMA Internal Medicine. 2014;174(12):1974-1981. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5416","journal-title":"JAMA Internal Medicine."},{"issue":"10","key":"9356_CR13","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/liv.14634","volume":"40","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Gicquelais RE, Astemborski J, et al. Hepatitis C Treatment Uptake among People who Inject Drugs in the Oral Direct-Acting Antiviral Era. Liver Int. 2020;40(10):2407-2416. https:\/\/doi.org\/10.1111\/liv.14634","journal-title":"Liver Int."},{"issue":"7","key":"9356_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/cid\/ciaa111","volume":"71","author":"SA Springer","year":"2020","unstructured":"Springer SA, del Rio C. Co-located Opioid Use Disorder and Hepatitis C Virus Treatment Is Not Only Right, But It Is Also the Smart Thing To Do as It Improves Outcomes! Clin Infect Dis. 2020;71(7):1723-1725. https:\/\/doi.org\/10.1093\/cid\/ciaa111","journal-title":"Clin Infect Dis."},{"issue":"Suppl 2","key":"9356_CR15","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1093\/cid\/cit296","volume":"57","author":"NK Martin","year":"2013","unstructured":"Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy. Clin Infect Dis. 2013;57(Suppl 2):S39-S45. https:\/\/doi.org\/10.1093\/cid\/cit296","journal-title":"Clin Infect Dis."},{"issue":"5","key":"9356_CR16","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/hep.26431","volume":"58","author":"NK Martin","year":"2013","unstructured":"Martin NK, Vickerman P, Grebely J, et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58(5):1598-1609. https:\/\/doi.org\/10.1002\/hep.26431","journal-title":"Hepatology."},{"issue":"6","key":"9356_CR17","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/hep.29685","volume":"67","author":"S Saab","year":"2018","unstructured":"Saab S, Le L, Saggi S, Sundaram V, Tong MJ. Toward the elimination of hepatitis C in the United States. Hepatology. 2018;67(6):2449-2459. https:\/\/doi.org\/10.1002\/hep.29685","journal-title":"Hepatology."},{"key":"9356_CR18","unstructured":"Falade-Nwulia O, Kim N. Addressing Structural Barriers to HCV Treatment - Evaluation and Preparation for Hepatitis C Treatment - Hepatitis C Online. University of Washington; 2024. Accessed July 23, 2024. https:\/\/www.hepatitisc.uw.edu\/go\/evaluation-treatment\/addressing-structural-barriers-to-treatment\/core-concept\/all"},{"key":"9356_CR19","doi-asserted-by":"publisher","unstructured":"Fleurence RL, Collins FS. A National Hepatitis C Elimination Program in the United States: A Historic Opportunity. JAMA. Published online March 9, 2023. https:\/\/doi.org\/10.1001\/jama.2023.3692","DOI":"10.1001\/jama.2023.3692"},{"key":"9356_CR20","unstructured":"U.S. Department of Health and Human Services. Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021\u20132025).; 2020. https:\/\/www.hhs.gov\/sites\/default\/files\/Viral-Hepatitis-National-Strategic-Plan-2021-2025.pdf"},{"key":"9356_CR21","unstructured":"Office of Infections Disease and HIV\/AIDS Policy (OIDP). Mapping Hepatitis Elimination in Action. hhs.gov. May 3, 2024. Accessed July 30, 2024. https:\/\/www.hhs.gov\/hepatitis\/programs-and-initiatives\/mapping-hepatitis-elimination-in-action\/index.html"},{"key":"9356_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.drugpo.2017.05.019","volume":"47","author":"J Grebely","year":"2017","unstructured":"Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017;47:51-60. https:\/\/doi.org\/10.1016\/j.drugpo.2017.05.019","journal-title":"Int J Drug Policy."},{"key":"9356_CR23","unstructured":"2024 National Snapshot Report. Hepatitis C: State of Medicaid Access. 2024. Accessed May 21, 2024. https:\/\/stateofhepc.org\/2024-national-snapshot-report\/"},{"issue":"7","key":"9356_CR24","doi-asserted-by":"publisher","first-page":"e2422406","DOI":"10.1001\/jamanetworkopen.2024.22406","volume":"7","author":"NW Furukawa","year":"2024","unstructured":"Furukawa NW, Ingber SZ, Symum H, et al. Medicaid Expansion and Restriction Policies for Hepatitis C Treatment. JAMA Network Open. 2024;7(7):e2422406. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.22406","journal-title":"JAMA Network Open."},{"issue":"8","key":"9356_CR25","doi-asserted-by":"publisher","first-page":"e2327326","DOI":"10.1001\/jamanetworkopen.2023.27326","volume":"6","author":"SN Kapadia","year":"2023","unstructured":"Kapadia SN, Zhang H, Gonzalez CJ, et al. Hepatitis C Treatment Initiation Among US Medicaid Enrollees. JAMA Netw Open. 2023;6(8):e2327326. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.27326","journal-title":"JAMA Netw Open."},{"key":"9356_CR26","unstructured":"HepVu.org. Hepatitis C Treatment Restrictions. HepVu. March 4, 2022. Accessed June 6, 2024. https:\/\/hepvu.org\/news-updates\/hepatitis-c-treatment-restrictions-2\/"},{"key":"9356_CR27","unstructured":"Hepatitis C State of Medicaid Access. Hepatitis C: State of Medicaid Access Report Card - Kentucky. Center for Health Law and Policy Innovation; National Viral Hepatitis Roundtable; 2024. Accessed April 26, 2024. https:\/\/stateofhepc.org\/wp-content\/uploads\/2021\/05\/Kentucky-February-2024_clean.pdf"},{"key":"9356_CR28","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BCE. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States. Health Aff Sch. 2023;1(1):qxad013. https:\/\/doi.org\/10.1093\/haschl\/qxad013","DOI":"10.1093\/haschl\/qxad013"},{"issue":"3","key":"9356_CR29","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","volume":"8","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Levin E, Dooling BCE. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. The Lancet Public Health. 2023;8(3):e238-e246. https:\/\/doi.org\/10.1016\/S2468-2667(23)00023-3","journal-title":"The Lancet Public Health."},{"issue":"3","key":"9356_CR30","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/QAI.0000000000001098","volume":"73","author":"MM Van Handel","year":"2016","unstructured":"Van Handel MM, Rose CE, Hallisey EJ, et al. County-level Vulnerability Assessment for Rapid Dissemination of HIV or HCV Infections among Persons who Inject Drugs, United States. J Acquir Immune Defic Syndr. 2016;73(3):323-331. https:\/\/doi.org\/10.1097\/QAI.0000000000001098","journal-title":"J Acquir Immune Defic Syndr."},{"key":"9356_CR31","unstructured":"Kentucky Department for Public Health. Hepatitis C Elimination Plan. Kentucky Department of Public Health; 2022. Accessed March 8, 2023. https:\/\/www.chfs.ky.gov\/agencies\/dph\/dehp\/idb\/Documents\/HepatitisCEliminationPlan.pdf"},{"key":"9356_CR32","unstructured":"Substance Abuse and Mental Health Services Administration. Interactive NSDUH State Estimates - Opioid Use Disorder in Past Year Among Adults Aged 18 or Older, by State. Accessed July 23, 2024. https:\/\/datatools.samhsa.gov\/saes\/state"},{"key":"9356_CR33","unstructured":"Centers for Disease Control. 2019\u20132020 Rates of Reported Acute Hepatitis C Cases. October 10, 2022. Accessed July 23, 2024. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2020surveillance\/hepatitis-c\/figure-3.2.htm"},{"issue":"5","key":"9356_CR34","first-page":"232","volume":"24","author":"C Isenhour","year":"2018","unstructured":"Isenhour C, Hariri S, Vellozzi C. Monitoring the Hepatitis C Care Cascade Using Administrative Claims Data. Am J Manag Care. 2018;24(5):232-238.","journal-title":"Am J Manag Care."},{"issue":"1","key":"9356_CR35","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27. https:\/\/doi.org\/10.1097\/00005650-199801000-00004","journal-title":"Med Care."},{"issue":"11","key":"9356_CR36","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83","journal-title":"Med Care."},{"key":"9356_CR37","unstructured":"Turner K. MCHP SAS Macro Code - ICD-10 Elixhauser Index. Concept: Elixhauser Comorbidity Index. November 27, 2021. Accessed May 14, 2024. http:\/\/mchp-appserv.cpe.umanitoba.ca\/Upload\/SAS\/_elixhauser_total.sas.txt"},{"issue":"9596","key":"9356_CR38","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X","journal-title":"Lancet."},{"key":"9356_CR39","doi-asserted-by":"publisher","unstructured":"American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1\u201391. https:\/\/doi.org\/10.1097\/ADM.0000000000000633","DOI":"10.1097\/ADM.0000000000000633"},{"issue":"2","key":"9356_CR40","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.idc.2018.02.001","volume":"32","author":"BL Norton","year":"2018","unstructured":"Norton BL, Akiyama MJ, Zamor PJ, Litwin AH. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice. Infectious Disease Clinics of North America. 2018;32(2):347-370. https:\/\/doi.org\/10.1016\/j.idc.2018.02.001","journal-title":"Infectious Disease Clinics of North America."},{"key":"9356_CR41","unstructured":"Delphin-Rittmon ME, Cohen MK. Advancing HIV and viral hepatitis testing with point-of-care diagnostics for people with substance use disorder. Published online December 9, 2024. Accessed December 27, 2024. https:\/\/www.cdc.gov\/hepatitis\/media\/pdfs\/2024\/12\/SAMHSA-CDC-DCL-HIV-Viral-Hepatitis-Testing-December-2024-508c_FINAL.pdf"},{"issue":"5","key":"9356_CR42","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.amepre.2021.05.017","volume":"61","author":"AM Harris","year":"2021","unstructured":"Harris AM, Khan MA, Osinubi A, Nelson NP, Thompson WW. Hepatitis C Treatment Among Commercially or Medicaid-Insured Individuals, 2014-2018. Am J Prev Med. 2021;61(5):716-723. https:\/\/doi.org\/10.1016\/j.amepre.2021.05.017","journal-title":"Am J Prev Med."},{"issue":"10","key":"9356_CR43","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/liv.14634","volume":"40","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Gicquelais RE, Astemborski J, et al. Hepatitis C Treatment Uptake among People who Inject Drugs in the Oral Direct-Acting Antiviral Era. Liver Int. 2020;40(10):2407-2416. https:\/\/doi.org\/10.1111\/liv.14634","journal-title":"Liver Int."},{"issue":"8","key":"9356_CR44","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/jama.2022.0293","volume":"327","author":"EU Patel","year":"2022","unstructured":"Patel EU, Genberg BL, Zhu X, Krawczyk N, Mehta SH, Tobian AAR. HIV and Hepatitis C Virus Testing and Treatment Services in Specialty Treatment Facilities That Offer Medication for Opioid Use Disorder in the US. JAMA. 2022;327(8):776-778. https:\/\/doi.org\/10.1001\/jama.2022.0293","journal-title":"JAMA."},{"key":"9356_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jsat.2016.12.014","volume":"75","author":"JL Butner","year":"2017","unstructured":"Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal of Substance Abuse Treatment. 2017;75:49-53. https:\/\/doi.org\/10.1016\/j.jsat.2016.12.014","journal-title":"Journal of Substance Abuse Treatment."},{"issue":"4","key":"9356_CR46","doi-asserted-by":"publisher","first-page":"ofy048","DOI":"10.1093\/ofid\/ofy048","volume":"5","author":"BJ Eckhardt","year":"2018","unstructured":"Eckhardt BJ, Scherer M, Winkelstein E, Marks K, Edlin BR. Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program. Open Forum Infect Dis. 2018;5(4):ofy048. https:\/\/doi.org\/10.1093\/ofid\/ofy048","journal-title":"Open Forum Infect Dis."},{"issue":"16","key":"9356_CR47","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1001\/jama.2024.2452","volume":"331","author":"AH Talal","year":"2024","unstructured":"Talal AH, Markatou M, Liu A, et al. Integrated Hepatitis C\u2013Opioid Use Disorder Care Through Facilitated Telemedicine: A Randomized Trial. JAMA. 2024;331(16):1369-1378. https:\/\/doi.org\/10.1001\/jama.2024.2452","journal-title":"JAMA."},{"key":"9356_CR48","unstructured":"Hepatitis C: State of Medicaid Access. Hepatitis C: State of Medicaid Access. 2024. Accessed July 25, 2024. https:\/\/stateofhepc.org\/"},{"issue":"5","key":"9356_CR49","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s11606-022-07860-3","volume":"38","author":"SN Kapadia","year":"2023","unstructured":"Kapadia SN, Zhang H, Gonzalez CJ, et al. Specialist and Primary Care Treatment of Hepatitis C Infections in US Medicaid in 2018. J GEN INTERN MED. 2023;38(5):1323-1325. https:\/\/doi.org\/10.1007\/s11606-022-07860-3","journal-title":"J GEN INTERN MED."},{"issue":"2","key":"9356_CR50","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11901-007-0005-8","volume":"6","author":"BR Edlin","year":"2007","unstructured":"Edlin BR, Carden MR, Ferrando SJ. Managing Hepatitis C in Users of Illicit Drugs. Curr Hepat Rep. 2007;6(2):60-67.","journal-title":"Curr Hepat Rep."},{"key":"9356_CR51","doi-asserted-by":"publisher","first-page":"102138","DOI":"10.1016\/j.pmedr.2023.102138","volume":"32","author":"H Park","year":"2023","unstructured":"Park H, Brown C, Wilson DL, et al. Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States. Prev Med Rep. 2023;32:102138. https:\/\/doi.org\/10.1016\/j.pmedr.2023.102138","journal-title":"Prev Med Rep."},{"key":"9356_CR52","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.1016\/j.drugpo.2021.103247","volume":"96","author":"A Amoako","year":"2021","unstructured":"Amoako A, Ortiz-Paredes D, Engler K, Lebouch\u00e9 B, Klein MB. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis. International Journal of Drug Policy. 2021;96:103247. https:\/\/doi.org\/10.1016\/j.drugpo.2021.103247","journal-title":"International Journal of Drug Policy."},{"issue":"3","key":"9356_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cld.1028","volume":"16","author":"B Cave","year":"2020","unstructured":"Cave B, Sanders K, Moser S, Brawley R, McCormick T, Espinosa C. Working Toward Elimination of Hepatitis C: The Kentucky Hepatitis Academic Mentorship Program. Clin Liver Dis (Hoboken). 2020;16(3):123-126. https:\/\/doi.org\/10.1002\/cld.1028","journal-title":"Clin Liver Dis (Hoboken)."},{"key":"9356_CR54","unstructured":"The ECHO Model. Project ECHO. Accessed June 7, 2024. https:\/\/projectecho.unm.edu\/model\/"},{"issue":"7","key":"9356_CR55","doi-asserted-by":"publisher","first-page":"e2115523","DOI":"10.1001\/jamanetworkopen.2021.15523","volume":"4","author":"L Tran","year":"2021","unstructured":"Tran L, Feldman R, Riley T III, Jung J. Association of the Extension for Community Healthcare Outcomes Project With Use of Direct-Acting Antiviral Treatment Among US Adults With Hepatitis C. JAMA Network Open. 2021;4(7):e2115523. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.15523","journal-title":"JAMA Network Open."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09356-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09356-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09356-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T01:01:49Z","timestamp":1768957309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09356-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":55,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["9356"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09356-2","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"Dr. Sugarman, Dr. Saloner, Dr. Harris, Dr. Bandara, and Ms. Flanagan reported receiving grants from Bloomberg Philanthropies during the conduct of the study. Dr. Bandara reported receiving grants from the National Institutes of Health and Centers for Disease Prevention and Control outside the submitted work. Dr. Irvin reported part-time work on federal detail at the National Institutes of Health on the national hepatitis C elimination plan outside the submitted work. Dr. Saloner reported personal fees from Susman Godfrey outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}